Interleukin 2 receptor targeted immunotherapy in the prevention of autoimmune beta-cell destruction as observed in diabetic BB/OK rats grafted with BB/OK rat islets.
Hahn
H J
HJ
Kauert
C
C
Dunger
A
A
Kuttler
B
B
Diamantstein
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D007111:Immunity, Cellular; D007167:Immunotherapy; D007515:Islets of Langerhans / Q000276:immunology* / Q000473:pathology; D016381:Islets of Langerhans Transplantation / Q000276:immunology; D051381:Rats; D011913:Rats, Inbred BB / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D016572:Cyclosporine